[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Organon and Co\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100613353",false,"NCT07265479","A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to \u003C 24 Months With Atopic Dermatitis","A Randomized, Double-Blind, Vehicle-Controlled (Period 1) and Open-Label (Period 2) Phase 3 Study to Investigate the Safety and Efficacy of Tapinarof Cream, 1% in Pediatric Participants Ages 3 Months to \u003C 24 Months With Atopic Dermatitis","Adoring","Inclusion Criteria:\n\n* Infants and toddlers born at term (≥37 weeks of gestational age) that are 3 months to \\\u003C24 months of age at the Screening visit.\n* Clinical diagnosis of atopic dermatitis (AD), AD covering \\>5% Body Surface Area (BSA) and validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of 2, 3 or 4\n* Legal guardian or primary caregiver is willing and able to sign informed consent form before any study-related activities\n* Legal guardian or primary caregiver is able and willing to adhere to protocol requirements\n\nExclusion Criteria:\n\n* Significant neurological disorder or history of seizure\n* Know clinically significant cardiac rhythm or cardiac disorder\n* History of sudden infant death in a sibling\n* Clinically significant chromosome abnormality\n* History of or ongoing serious illness or medical, physical or psychiatric condition(s) that may interfere with the participant's participation\n* Diseases that could cause pruritic and\u002For sleep disruption\n* Immunocompromised\n* Current chronic or acute infection requiring treatment\n* Use of prohibited medication(s) or procedure(s)\n* Use of prohibited medications by breastfeeding mother if breastfeeding participant","ALL","3 Months","23 Months",{"count":20,"type":21},180,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.",[27],"Atopic Dermatitis",[29,30,31,32],"Pediatric Atopic Dermatitis","Eczema","tapinarof","topical","RECRUITING","2026-06-03",{"date":36,"type":37},"2026-06-04","ACTUAL",{"date":39,"type":37},"2025-12-29",{"date":41,"type":21},"2028-01",{"name":43,"class":44},"Organon and Co","INDUSTRY",47,""]